ApexOnco @ApexOnco · Nov 2, Nov 2, 2026, 3:56 PM No advance for $AZN Avanzarapexonco.com/node/2459 www.apexonco.com No advance for Avanzar The key pivotal study of Datroway is delayed yet again.
ApexOnco @ApexOnco · Oct 15, Oct 15, 2026, 10:49 AM Anktiva's papillary-only expansion $IBRX apexonco.com/node/2412 www.apexonco.com Anktiva bags a papillary expansion Previous data, plus similarities with carcinoma in situ, are enough for the FDA.
ApexOnco @ApexOnco · Oct 12, Oct 12, 2026, 3:07 PM $NVS Lutathera sees its third challenge $BMY $LNTHapexonco.com/node/2404 www.apexonco.com Lutathera sees its third challenge After the approvals of two equivalents, the Novartis drug could be challenged by Bristol’s actinium-based therapy.
ApexOnco @ApexOnco · Oct 9, Oct 9, 2026, 7:29 AM Full TEAD ahead for Vivaceapexonco.com/full-tead-ahea… www.apexonco.com Full TEAD ahead for Vivace The company will start the phase 3 Steadfast study of VT3989 in December.
ApexOnco @ApexOnco · Oct 1, Oct 1, 2026, 12:20 PM $MRK, SciBrunch, $RVMD, $ERAS, Joyo, $AZN, Usynova – and the WuXi connectionapexonco.com/node/2380 www.apexonco.com Analysis: SciBrunch, Revolution and the WuXi connection The Chinese contract manufacturer sits at the heart of several recent KRAS deals, and a key dispute.
